Codexis

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Codexis reports strong 2022 performance, eyes growth in Life Sciences

Codexis made significant progress in 2022, focusing on high-value programs and enhancing technical capabilities.
While facing challenges in managing expenses and revenue variability, the company is well-positioned with a strong cash position and growth opportunities.
Strategic collaborations and revenue diversification efforts position Codexis for sustainable growth and value creation in the future.

Codexis navigates revenue challenges, eyes growth through strategic partnerships

Codexis is strategically focusing on the ECO Synthesis platform and pharmaceutical manufacturing business for revenue growth and positive cash flow by 2026.
While facing challenges such as impairments on investments and revenue timing, the company is leveraging opportunities through partnerships and operational improvements.
The company's financial discipline, strong balance sheet, and key collaborations position it well for future growth and success in the pharmaceutical manufacturing sector.
With ongoing negotiations and advancements in technology, Codexis is poised for continued progress and innovation in the enzymatic solutions market.

Codexis reports robust Q4 performance, eyes growth through strategic partnerships

Codexis delivered a strong performance in Q4 2023, driven by strategic decisions, partnerships, and financial results showcasing growth potential.
The company's focus on expanding the ECO Synthesis platform and pharmaceutical manufacturing bodes well for sustained revenue growth.
While facing challenges in scaling operations and managing expenses, Codexis is well-positioned to capitalize on market opportunities and drive innovation.

Codexis projects 10% revenue growth, advances in RNA synthesis

Codexis is poised for growth in 2024, with a focus on revenue expansion, product innovation, and strategic partnerships to drive market success.
The company's strong performance in supplying enzymes for various programs underscores its market leadership and technological capabilities.
While facing challenges in diversifying its customer base and sustaining growth, Codexis is leveraging its strengths in technology and innovation to seize emerging opportunities.

Codexis reports Q3 revenue growth, eyes profitability amid strategic investments

Codexis navigates Q3 2024 with revenue growth in pharma manufacturing and strategic investments for future profitability.
Despite a net loss, the company maintains financial stability with a strong cash position and a focus on enhancing capabilities.
Challenges lie in achieving profitability by 2026, managing divestiture impacts, and optimizing gross margins amid operational changes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Assignment results in estimated cumulative cash savings of more than $30M and supports projected cash runway to mid-2026 Assignment results in estimated cumulative cash savings of more than $30M and supports projected cash runway to mid-2026

Codexis Announces Agreement for Assignment and Assumption of San Carlos Facility Lease

Archer Aviation

Ginkgo Bioworks Holdings

908 Devices

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Cathie Wood's ARK Funds Continue to Buy These 5 Stellar ‘Strong Buy' Stocks Trading Under $10

Codexis (CDXS) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.04 per share a year ago.

Codexis (CDXS) Reports Q2 Loss, Lags Revenue Estimates

Company Recently Announced Enhanced Strategic Focus and Portfolio Prioritization Anticipate Demonstrating Gram-Scale Synthesis of ECO Synthesis™ Technology for RNAi Therapeutics Production by End of Year Projected Cash Runway to Mid-2026 Funds Important ECO Synthesis™ Milestones Through Commercialization REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the second quarter ended June 30, 2023, and provided a business update.

Codexis Reports Second Quarter 2023 Financial Results

New Film Highlights Company Commitment to Transforming RNAi Therapeutics Landscape New Film Highlights Company Commitment to Transforming RNAi Therapeutics Landscape

Codexis Documentary Showcases its Specialized Capabilities Engineering High Performance Enzymes to Enable Delivery of Novel Therapeutics

Organization Streamlined to Focus on Continued Advancement and Commercialization of ECO Synthesis™ Platform for RNAi Therapeutics Production

Codexis Announces Enhanced Strategic Focus and Extends Projected Cash Runway to Mid-2026

Beyond Meat

Gevo

The synthetic biology boom of the pandemic era has become a synthetic biology bust. Many synthetic biology stocks promised the moon and delivered mud.

Time to Evolve: 3 Synthetic Biology Stocks to Sell Off Now

Codexis (CDXS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.13 per share a year ago.

Codexis (CDXS) Reports Q1 Loss, Lags Revenue Estimates

Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?

REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of market. The Company will not be conducting a conference call in conjunction with this financial results release.

Codexis to Report First Quarter 2023 Financial Results on May 4

REDWOOD CITY, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a pre-conference workshop highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES USA annual meeting being held May 7-10, 2023, in San Diego, CA. The workshop will be held live and virtually on Sunday, May 7, 2023.

Codexis Announces RNA Therapeutics Manufacturing Workshop at TIDES USA

REDWOOD CITY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that Patrick Yang, PhD, will not seek re-election to the Codexis Board of Directors. Dr. Yang joined the Board in 2014 and served as the Chair of the Nominating and Corporate Governance Committee.

Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors

Codexis, Inc. (NASDAQ:CDXS ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Stephen Dilly - President, CEO & Director Kevin Norrett - COO Sriram Ryali - CFO Conference Call Participants Steven Mah - Cowen Company Brandon Couillard - Jefferies Matthew Hewitt - Craig-Hallum Operator Welcome to the Codexis Fourth Quarter and Full Year 2022 Earnings Conference Call. A question-and-answer session will follow the formal presentation.

Codexis, Inc. (CDXS) Q4 2022 Earnings Call Transcript

Codexis (CDXS) delivered earnings and revenue surprises of 17.39% and 4.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates

Biotherapeutics Application of CodeEvolver® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational New Drug Applications

Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results

REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today highlights several key presentations from its gene therapy programs from 19 th Annual WORLDSymposium™, taking place from February 22-26, 2023, in Orlando, Florida.

Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™

REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2022 on Thursday, February 23, 2023, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update.

Codexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23

REDWOOD CITY, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Sri Ryali as Chief Financial Officer effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in life sciences to Codexis. In this role, Mr. Ryali will lead all aspects of the Company's financial operations and will report directly to Dr. Stephen Dilly, President and Chief Executive Officer of Codexis.

Codexis Announces Appointment of Sri Ryali as Chief Financial Officer

REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors.

Codexis Announces Appointment of H. Stewart Parker to Board of Directors

REDWOOD CITY, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced an update on the Company's ongoing plan to prioritize its time and resources on areas where the Company believes it has the strongest commercial opportunity and greatest probability of success. As part of this plan, the Company has decided to discontinue investment in certain internal development programs, expand investment in high potential development programs and reduce its workforce by approximately 18%.

Codexis Provides Update on Prioritized Corporate Strategy

REDWOOD CITY, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference, being held on November 29-December 1, 2022, in New York, New York.

Codexis to Participate in Piper Sandler 34th Annual Healthcare Conference

The consensus price target hints at a 219.4% upside potential for Codexis (CDXS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Codexis (CDXS)? Wall Street Analysts Think 219%

Codexis, Inc. (NASDAQ:CDXS ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Brendan Strong - Argot Partners Dr. Stephen Dilly - President and Chief Executive Officer Kevin Norrett - Chief Operating Officer Ross Taylor - Chief Financial Officer Conference Call Participants Chad Wiatrowski - Cowen and Company Matthew Hewitt - Craig-Hallum Capital Group Operator Welcome to the Codexis Third Quarter 2022 Earnings Conference Call. At this time, all participants are in listen-only mode.

Codexis, Inc. (CDXS) Q3 2022 Earnings Call Transcript

Reiterates 2022 Total Revenue Guidance of $135M-$141M, Including Product Revenues of $112M-$118M Reiterates 2022 Total Revenue Guidance of $135M-$141M, Including Product Revenues of $112M-$118M

Codexis Reports Third Quarter 2022 Financial Results

REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2022 on Thursday, November 3, 2022, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update.

News for Codexis Stock (CDXS)